Unlocking the brain to biologics
About us
Key2Brain is a Swedish biotechnology company committed to developing a novel and efficacious brain targeting platform technology.
With unique molecules and preclinical expertise, Key2Brain provides solutions for enhanced brain uptake of biologics and diagnostics. Key2Brain is a partner for preclinical development of therapeutics treating the central nervous system (CNS).
Our goal is to improve treatment and diagnostic options for diseases of the CNS.
The technology
Key2Brain is developing a proprietary technology to enable brain access to biopharmaceuticals. Please contact us to learn more.
Our expertise
With extensive experience in drug discovery and development of biologics, our team will facilitate a preclinical way towards clinic, using our technology.
Collaboration and Partnership
Key2Brain is a semi-virtual company. Our business model relies on collaboration and partnership with academia and industry. Please contact us to know more.
The Team
Operations
Chao Su, PhD
Principal Scientist
Tiffany Dallas, MSc
Scientist
Anette Åqvist
Commercial Lead
Magnus Berglund, PhD
Chief Technical Officer
Elisabet Sjöström, PhD
Founder, CEO
Scientific Advisory Board
Anna Sandegren, PhD
Tobias Cornvik, PhD
Stephen James, PhD
Stefan S Gelius, PhD
Board of Directors
Board Member, Andreas Gretander
Board Member, Stephen James
Board Member, Nina Fleck
Vice chair,
Kristina Magnusson Borg
Chair,
Elisabet O Sjöström
Photo: Rebecca Faresjö, Magnus Berglund
Contact
Email
info@key2brain.se
Visit us
Karolinska Institute Campus, Innomedicum, A Working Lab (AWL)
Nanna Svartz Väg 4, Solna
News
-
Key2Brain awarded VINNOVA funding
May 2023 -
Key2Brain was in May 2023 awarded “Innovative start-ups grant step 2” from VINNOVA, Sweden’s Innovation Agency
-
Team Expansion
June 2023 -
Key2Brain has expanded the team with core competence within Business Development and Science
-
Funding: VINNOVA Acceleration for deeptech companies
November 2023 -
Once again Key2Brain is supported by VINNOVA to accelerate our technology development
SEK 1 m funded for the first stage, with a possibility to get up to SEK 4 m in total over 3 years.